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Abstract— The human heart tissue has a limited capacity for
regeneration. Tissue and cellular therapies based on the use
of stem cells may be useful alternatives to limit the size of
myocardial infarction. In this paper, the preliminary results
from an experimental campaign for on-line monitoring of
myocardium scar infarction are presented. This study has been
carried out under a research project that has as main objective
the development and application of a bioactive patch implant
for regeneration of myocardial infarction. Electrical Impedance
Spectroscopy (EIS) has been chosen as a tissue state monitoring
technique. What is presented in this communication is the first
results of an implantable EIS measurement system which has
been implanted in a subset of the animals corresponding to
the control group, along one month. In all the animals, the
myocardial infarction was induced by the ligation of the first
circumflex marginal artery. In the animal group presented,
the bioactive patch scaffold and the electrodes were implanted
without the stem cells load. The scaffold is a piece of decel-
lularized human pericardium, lyophilized and rehydrated with
hydrogel RAD16-I. Nanogold particles were also placed near
the electrodes to improve the electrode area conductivity. The
results presented correspond to the subset of animals (n = 5),
which had implanted the bioimpedance system monitoring the
electrical impedance spectrum in vivo during 1 month. Two
electrodes were connected to the bioactive patch implant. A
total of 14 logarithmically spaced frequencies were measured
every 5 minutes, from 100 Hz to 200 kHz. Results show a
convergence of low-frequency and high frequency impedance
magnitudes along the measurement period, which is coherent
with the scar formation.
I. INTRODUCTION
Heart failure is the end-stage of many cardiovascular
diseases. One of the main problems is the presence of
necrotic tissue due to an acute myocardial infarction which
deeply affects heart function. Due to myocardium has very
limited regeneration capacity and the number of transplant
donors hardly meets the demand of potential recipients, new
therapeutic approaches to recover this function are highly
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required. Current treatments under development are looking
for effective and less invasive treatments, hence therapies
based on stem cells open a new world of possibilities since
they can divide and differentiate into different specialized
cell types.
One of the major concerns about tissue engineering for
cardiac regeneration is to promote the regeneration or eventu-
ally replace necrotic tissue that has been lost or compromised
i.e. due to an infarct, by a functional biological grafts. Ideally,
an engineered graft should be able to recover, maintain, or
even enhance the tissue functionality, being integrated with
the host tissue in response to the native environmental factors
[1]
Engineered tissues are usually developed in vitro for
an in vivo implantation to direct remodeling and repara-
tion/regeneration of tissues with the aim to enhance partial
or total tissue function. Some authors show the beneficial
effects of these platforms [2], [3]. However, controling the
location of grafted cells after transplantation is difficult, since
myocardium is a highly vascularized tissue. In general, there
are two main approaches in tissue engineering field. The first
consists in using isolated cells as replacement parts. The
second, cell encapsulation into natural or artificial bioma-
terials (collagens, polymeric fibers, respectively) capable of
inducing tissue regeneration, which could be a better option
to maintain the cells in the infarcted zone [4].
The final aim of the research project is the develop-
ment of an implanable bioactive patch to regenerate my-
ocardium tissue. The development and results presented in
this manuscript are focused only in a particular aspect,
which is the on-line monitor of the tissue state in a non-
destructive way by incorporating the sensing electrodes to the
biocompatible membrane. The ultimate goal is to evaluate
the beneficial effect of the membrane developed ad hoc
in a porcine model of myocardial infarction monitoring
the myocardial viability evolution through an implantable
electronic system.
II. SYSTEM DESCRIPTION
The prototype used for the experimental measurements
was originally presented in [5] where the system and char-
acterization results were described. Five improved replicas
were built for the measurement campaign. The bioimpedance
measurement system is a custom implantable bioimpedance
meter with a wireless Zigbee link. A block diagram is show
in Figure 1. The main parts are: (1) a device that enables
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the measurement of tissue impedance, (2) a wireless link to
transmit impedance data and (3) a computer to log, process
and display data. The bioimpedance measuring device is
based on the AD5933 from Analog Devices and the MSP430
microcontroller from Texas Instruments. The system enables
measurements at 4 and 2 electrodes every 5 minutes (pro-
grammable) for 14 different frequencies selectable between
100 Hz and 200 kHz. The measured impedance range is
between 10 Ω and 10 kΩ. An analog front end has been
implemented to enable the measurement of low impedances
trough high electrode impedances. The front end consists in a
voltage controlled current source with a bandwidth of 1 MHz
to inject an ac current to the tissue under measurement, which
is controlled by the AD5933 signal generator and is limited
to 10 µApp. A wide-bandwidth differential voltage amplifier
measures the voltage drop between electrodes. The system
monitors the real an imaginary parts of the impedance under
test, the battery level and the internal temperature. All these
data are sent to the computer through the Zigbee wireless
network and are also stored into a flash memory which
content can be uploaded through the Zigbee link in situ or
after extracting the device from the animal. The electrodes
are built from a modified DSI Coupler Lead, Data Science
International, by leaving the distal end (5 mm) uncoated and
with only one of the two imbricated spirals. This allows
the easy and robust connection of the spiral winding to
the pericardial piece and also its sterilization by gamma
radiation. In the subsequent hydration of the pericardium,
when the hydrogel is formed, the mechanical properties of
the set are maintained.
Fig. 1. Draft of the implemented system. Several bioimpedance monitors
are implanted and connected to the receiver Access Point. See text for
details.
The implantable system is powered by a Li-ion battery
(3.7 V) with 1000 mAh capacity. The digital part of the
system is powered at 3.3 volts whereas the analog sub-
circuits and the wireless device are powered at ± 2.8 volts.
The microcontroller is in charge on managing the power-
up and power-down of analog and RF parts of the system
in order to reduce the global system consumption. The data
packet sent is as follows: one byte for the device identifier (to
enable multiple device monitoring), one byte for the Receiver
Signal Strength Indication (RSSI) value, one byte for the
measured frequency and two bytes for each the real and
the imaginary parts. Then the temperature and the battery
voltage respectively (11 Bytes each). A LabVIEW program
has been implemented to receive the data in a computer. The
program provides a serial communication with the access
point, receives and processes the data and stores them in a
file.
III. METHODS
A. Scaffold
The structure of the bioactive patch is formed by a
piece of decellularized human pericardium by treatment
with detergents. The metallic electrodes are anchored to
the pericardium before the sterilization and hydratation.
The electrical connection with the matrix is improved by
permeating the region with a solution of nanogold to favor
the flow of electrical current within the biological membrane
to the peptide hydrogel. This solution is only applied to the
area where the electrodes are nested in the pericardial piece.
RAD16-I peptide hydrogel is used to fill in the decellular-
ized human pericardium scaffold. RAD16-I is commercially
available under the name of PuramatrixTM (BD, Erem-
bodegem, Belgium). This peptide is an ideal candidate as cell
culture matrix in tissue engineering since its biomechanical
properties are similar to natural extracellular matrices [6].
It provides a convenient mechanism for self-assembly into
highly organized nanostructures associated with 3D network
formation, which may promote cell adhesion, spreading,
migration, growth and differentiation. Extensive studies have
already indicated their good biocompatibility and biodegrad-
ability [7].
B. Bioimpedance monitor encapsulation
The bioimpedance monitors (60mmx45mmx24mm) were
covered with a biocompatible polydimethylsiloxane silicone
(PDMS) (Sylgard, 184, Dow Corning Corp.). The PDMS was
prepared by mixing two liquid components in a ratio of 10
parts base to one part curing agent in a liquid state (10:1, by
weight) (Sylgard, 184, Dow Corning Corp.). Air introduced
into the mixture during stirring was removed by using a
vacuum chamber at 700 mbar for 30 minutes. Then, the
mixture was smoothly poured over the bioimpedance system
box. To shorten the curing time, the mixture was cured in an
oven (60 Celsius degrees, 2.5-3h). The implantable systems
were sterilised by prior to the implantation using chemical
agents.
C. Animal preparation
Human pericardium was obtained from patients undergo-
ing cardiac surgery. This protocol was approved by the local
Ethics Committee, and informed consent was obtained from
all patients. The study protocol conformed to the principles
outlined in the Declaration of Helsinki.
A total of 5 Pigs (20−30 kg) were premedicated with an
IM mixture of ketamine (20 mg/kg), diazepam (0.25 mg/kg),
and atropine (0.25 mg/kg). Anesthetic induction was done
with an IV propofol bolus (4 mg/kg). Animals underwent
endotracheal intubation, and anesthesia was maintained by
2% sevofluorane inhalation. A continued IV infusion of Ke-
torolac (0.15 mg/kg/h) and tramadol (0.5 mg/kg/h) was used
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as an intraoperatory analgesic. At the beginning of the inter-
vention, an IV lidocaine bolus (1 mg/kg) was administered,
followed by a continuous infusion (1 mg/kg/h) maintained
for 1 h after myocardial infarction (MI) induction. At the
end of the surgery, 2.5 mg/kg of tulatromicin, IM (Draxxin
reg., Pfizer) was administered as antibiotic therapy.
Acute MI was induced by a double-ligation (Prolene 5/0)
of the first marginal branch of the circumflex coronary
artery, 1.5 cm distal from the atrioventricular groove. 30
minutes after MI induction, the bioactive patch connected
to the bioimpedance monitoring system was implanted with
surgical glue (Glubran2) covering the infarcted area. All
procedures were done under monitoring conditions with
ECG registration and measures of capnography, pulse oxime-
try, non-invasive arterial blood pressure and temperature.
Animals underwent magnetic resonance imaging (MRI) at
multiple time points (baseline, 2 h and 1 month after MI)
to assess functional recovery. All pigs were sacrificed at 1
month to obtain samples for the histological analysis.
IV. EXPERIMENTAL RESULTS
A total of 7 animals comprised the control group. In all
animals myocardial infarction was induced by ligation of
the first circumflex marginal artery. In the control group
the membrane (decellularized pericardium, lyophilized and
rehydrated with nanogold and hydrogel) was implanted. In a
subset of 5 animals, five replicas of the bioimpedance mon-
itor were implanted and connected to the electrode cables
which were attached to the bioactive patch to monitor tissue
EIS in vivo. The performance of the network formed by the
telemetry equipment and the external implantable receiver
advised to reduce to 5 the number of systems in simultaneous
operation. During the course of the experimental measure-
ments, we have collaborated with the Minimally Invasive
Surgery Center Jesus Uson (CCMIJU) in Caceres, Spain,
where the model of acute MI in pigs and the measurement
of cardiac function by magnetic resonance imaging was
performed.
A. Implantation of the bioimpedance monitoring system
Figure 2 shows a detail of the bioactive patch with the
electrodes and the first section of cable, which is sterilized by
gamma radiation, and the process of implementing the patch,
the connection of cables with the implantable system, which
has been introduced through an auxiliary access practiced in
the animal shoulder.
Next, Figure 3 shows the implantable system closed and
sealed with biocompatible silicone (Sylgard 184) as specified
in Section III as well as the measurement setup at the
animal care center. Furthermore, it was possible to remotely
monitorize the evolution of the MI ischemia just using the
remote desktop. The goal of this feature was to detect
anomalies in the measurements, for example, due to poor
electrode contact in the bioactive patch implant, but the batch
upload of the full memory content of each device was used
in practice.
Fig. 2. Detail of the implant with the electrodes and the first section of
cable, which is sterilized by gamma radiation (left). Subcutaneous location
of the bioimpedance implanted system (right).
Fig. 3. From left to right: implantable system sealed with biocompatible
silicone. Telemetry system in the animal care center: the receiving antenna
was oriented toward animals monitored to improve the quality of data
transmission. The antenna was connected to the receiving system using
a coaxial cable. Through the labview management program, the received
data were stored in text files. Magnitude and phase angle of impedance
data were also displayed for each animal being measured (n=5). From the
systems implanted, we could retrieved measures from 4 of them (one of
them was destroyed by the animal).
B. Long-term monitoring of myocardial infarct scar
The estimates on the state of the tissue that may arise,
according to the literature and in vivo measurements obtained
by the group in previous projects, derived from measure-
ments of magnitude and phase angle at low (around 10 kHz)
and high (around 200 kHz) frequencies, and variations on the
ratio between them. Following Figure 4 shows the evolution
of the impedance magnitude at three consecutive frequencies
measured in a control animal. To filter the noise and artifacts
into the measurements, a median and a moving average filter
was used at each frequency and the measurement at low and
high frequency measurements were obtained by averaging
measurements at three frequencies in each range.
Fig. 4. Evolution of the impedance magnitude at low frequency in a control
animal. Three consecutive frequencies are represented.
Figure 5 shows the evolution of the impedance magnitude
at low (around 10 kHz) and high (around 100 kHz) measured
in two different animals from the control group. A systematic
increase of the initial magnitude can be observed. This is
coherent with the previously described impedance increase
in the acute ischemia [8] but can also be due to the patch
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and electrodes integration with the tissue. Then comes a
maintenance phase. There is a period with greater separation
between low and high frequencies which could corresponds
to the lysis of cells and scar formation finishing between
4,5 and 7 days after infarction. Finally, the stationary phase
where both low and high frequency impedance magnitude
have the same value, which is coherent with the previously
described resistive behaviour of the myocardium scar. The
final drop in the impedance corresponds to the depletion of
the battery, which happened before the calculated 1 month
period in all systems, ranging from 10 to 25 days.
Fig. 5. Evolution of the impedance magnitude at low and high frequency
in two control animals.
V. DISCUSSION
Although previous validation carried out with the first built
unit, we have found problems that limited their network
operation in long periods. In practice, the coexistence of
the five systems and the actual attenuation of the telemetry
signal gave error rates higher than those found with a single
unit, described in [5]. Both the embedded microcontroller
and computer control software were redesigned to provide
higher performance and system management and retrieval
capabilities of the harvested data.
Although these results are preliminary, we must em-
phasize that, to the best of our knowledge, there are no
previous descriptions in the literature on measurements of
these characteristics. The development of an implantable EIS
monitoring system that incorporates miniaturized telemetry
has enabled continuous EIS measurements at 14 frequencies
every 5 minutes during 1 month in pigs. The results are
coherent with the already known behavior of the three tissue
states: normal, acute ischemia and healed scar and provide
clues about the dynamics of the transition between these
states.
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